MedTrace Logo

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

NCT04222725 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2021-10-14

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.

Conditions

  • Post Surgical Ocular Inflammation

Interventions

DRUG

TRS01 eye drops

Dosed 4 times a day (QID)

DRUG

TRS01 eye drops

Dosed QID

DRUG

TRS01 eye drops

Dosed QID

DRUG

Placebo eye drops

Dosed QID

Sponsors & Collaborators

  • Tarsier Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-07-17
Completion
2020-07-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04222725 on ClinicalTrials.gov